Abstract Brain extracellular matrix (ECM) is a highly organized system that consists of collagens, noncollagenous proteins, glycoproteins, hyaluronan, and proteoglycans. Recognized physiological roles of ECM include developmental regulation, tissue homeostasis, cell migration, cell proliferation, cell differentiation, neuronal plasticity, and neurite outgrowth. Aberrant ECM structure is associated with brain neurodegenerative conditions. This review focuses on two neurodegenerative conditions, schizophrenia and Alzheimer's disease, and summarizes recent findings of altered ECM components, including proteoglycans, glycosaminoglycans, proteins, and glycoproteins, and proteins and genes related to other brain components. The scope includes immunohistochemical, genomics, transcriptomics, proteomics, and glycomics studies, and a critical assessment of current state of proteomic studies for neurodegenerative disorders. The intent is to summarize the ECM molecular alterations associated with neurodegenerative pathophysiology.
Introduction
Extracellular matrix (ECM) constitutes approximately 20 % of the adult brain volume [1] and has become a focus of neurological research. The functional roles of ECM include developmental regulation, tissue homeostasis, cell migration, cell proliferation, and cell differentiation [2] . The constituents of ECM include collagenous and noncollagenous proteins, glycoproteins, hyaluronan, and proteoglycans (PGs) [2] . PGs are proteins glycosylated with glycosaminoglycan (GAG) chains. GAGs play essential roles in all areas of physiology through their biophysical properties and capacities to bind growth factors and growth factor receptors. Thus, there is a keen interest in the roles of PG neuronal functions, including cell adhesion, cell migration, cell regeneration, ECM assembly, neurite outgrowth, and neurite plasticity [3] . PG structure is regulated in a spatial and temporal manner. As a result, the structures and functions of PGs in ECM depend on expression of core proteins via the endoplasmic reticulum and Golgi apparatus-mediated assembly of GAG chains attached to the core protein. Because the biosynthetic reactions do not go to completion, the GAG chains on PGs are heterogeneous with respect to chain length and modifications.
Neurodegenerative diseases, including schizophrenia (SZ), Alzheimer's disease (AD), multiple sclerosis, Parkinson's disease, and human immunodeficiency virus dementia, result from gradual and progressive loss of neural cells and changes in ECM components that lead to brain dysfunction [4] [5] [6] [7] . This review focuses on changes in ECM components, specifically PGs and GAGs, in SZ and AD. A better understanding of these changes in ECM components will help unravel the biomolecular mechanisms related to complex neurodegenerative conditions in the human brain.
GAGs are classified into five major types on the basis of the disaccharide unit; heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate (KS), and hyaluronan. HS and CS/DS are unbranched polymers composed of approximately 20-200 repeating disaccharide units attached to a serine or threonine residue of the core protein through a characteristic tetrasaccharide linker [8] . The disaccharide units contain either of two modified sugars, Nacetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc), and a uronic acid (either glucuronic acid or iduronic acid). The structures of the GAG classes are shown in Table 1 .
The four PG classes include interstitial PGs, which are present in the ECM, basement membrane PGs, secretory granule PGs, and membrane-bound PGs [9] . Interstitial PGs are a critical component of ECM involved in stabilization and organization of collagen fibers. The interstitial PGs include small leucine-rich PGs such as decorin, asporin, lumican, and biglycan [9, 10] , and hyalectans, including aggrecan, versican, neurocan, and brevican [11] . The major PG found in cytoplasmic secretory granules is serglycin. It has heparin and/or CS chains attached to the core protein. It binds to several chemokines, growth factors, and inflammatory mediators, and modulates their bioactivity. Basement membrane PGs include HSPGs perlecan, agrin, and collagen type XVIII, and leprecan. They mainly have HS chains attached to the core protein, except for the CSPG leprecan [12] . These PGs play important roles in cell adhesion, cell proliferation, growth factor signaling, embryogenesis, tissue morphogenesis, and cartilage development [12] [13] [14] . The membrane-bound syndecans and glypicans are involved in processes such as cell growth and angiogenesis [15, 16] . The syndecan family consists of four members, syndecans 1, 2, 3, and 4, which carry HS and/or CS chains. On the other hand, glypicans consist of six members, glypicans 1, 2, 3, 4, 5, and 6 attached to the plasma membrane via a glycosyl phosphatidylinositol anchor and carrying only HS chains. CSPG4 is a single-pass, type 1 transmembrane PG that carries one CS chain [9] .
The functions of hyalectans in brain ECM are related to modulation of cell adhesion and migration [17] . The C-type lectin domain of hyalectans mediates binding to other ECM proteins [18] , whereas the epidermal growth factor (EGF)-like repeats make hyalectans suitable for growth control [19] . The roles of hyalectans in neurite outgrowth are also well recognized [20] . Studies have shown that all four hyalectans inhibit neurite outgrowth in various neuronal cell types, through the CS chains [21] [22] [23] . A recent study showed a significant reduction in neurite outgrowth in vitro in the presence of ECM components, including aggrecan, brevican, and tenascin R [24] .
Hyaluronan (HA) is an important component of brain ECM. It binds to growth factors and cytokines, including transforming growth factor β, tumor necrosis factor α, EGF, and keratinocytes [25] . Exogenous HA induces mesenchymal properties of epithelial cells, and digestion of HA by hyaluronidase disrupts epithelial-mesenchymal transition [26, 27] . Both an increase and a decrease of hyaluronidase levels have been observed during tumorigenesis [28] .
Function and composition of brain ECM
As shown in Fig. 1 , brain ECM consists of relatively small amounts of fibrous proteins such as collagens and fibronectin and relatively high proportion of PGs and hyaluronan. Brain hyalectans include aggrecan (210-kDa protein chain, CS and KS GAGs), neurocan (136-kDa protein chain, CS and DS GAGs), brevican (145-kDa protein chain, CS GAGs), and versican (265-kDa protein chain, CS and DS GAGs) [29] . Brain small leucine-rich PGs include asporin (39-kDa protein chain, CS and DS GAGs), fibromodulin (42-kDa protein chain, KS GAGs), lumican (40-kDa protein chain, KS GAGs), biglycan (42 kDa, CS and DS GAGs), and decorin (40 kDa, CS and DS GAGs) [2] . Glycoproteins including collagens, laminins, tenascin, reelin, and fibronectin are among other components of the brain ECM.
ECM PGs interact with brain ligands, including growth factors, cell adhesion molecules, matrix components, and enzymes. This binding becomes considerably affected by variation in the GAG chains that influences the accessibility of ligands to cell surface receptors. The activity of growth factors may be either potentiated or inhibited by their interactions with ECM molecules. For example, vascular endothelial growth factor and platelet-derived growth factor bind heparin/HS, which in turn modulates their biological activity [30, 31] . The CSPG phosphacan binds to fibroblast growth factors and potentiates their mitogenic activities [32] . Among brain ECM structures, perineuronal nets (PNNs) are differentially distributed, highlighting their importance in brain physiology [24] . First described by Camillo Golgi and Santiago Ramón y Cajal in 1890, PNNs are highly organized reticular networks composed of ECM molecules surrounding Table 1 Glycosaminoglycan (GAG) repeating unit structures: hyaluronan, heparan sulfate (including heparin), chondroitin sulfate, dermatan sulfate, and keratan sulfate GalNAc N-acetylgalactosamine, GlcA glucuronic acid, GlcNAc N-acetylglucosamine, IdoA iduronic acid neuronal cell bodies and proximal dendrites [33] . PNNs consist of hyalectan PGs, tenascin C, tenascin R, hyaluronan, and PG-binding link proteins (hyaluronan and PG link protein 1/ cartilage link protein 1, and hyaluronan and PG link protein 4/ brain link protein 2). PNNs surrounding neurons carry three main components: a hyaluronan synthase, a link protein (usually cartilage link protein 1), and a CSPG (usually aggrecan). The physiological role of PNNs is not yet well established; however, their postnatal appearance suggests a role in restricting the development of new synaptic contacts: synapse formation and synaptic plasticity [11] . In line with this, a study showed the development of synapses in parallel with the emergence of PNNs [34] . PNNs are observed ensheathing neurons, suggesting a supportive role in providing a microenvironment for neurons [35] .
Changes in brain ECM in neurodegenerative conditions
Schizophrenia Schizophrenia (SZ) is a serious brain disorder affecting approximately 1 % of the population worldwide. The clinical symptoms of SZ appear during late adolescence or early adulthood when cognitive functions, including reasoning, thinking, and planning, achieve maturation [36] . Characterized by defects in thinking and decision-making ability, SZ is defined by positive (hallucinations and delusions) and negative (affective flattening and cognitive deficits) symptoms [37] . Currently, antipsychotic medications are the only treatment available for SZ. Treatment provides relief to a subset of schizophrenic patients but does not appear to impact the disease outcome significantly. Thus, lack of appropriate and effective treatment demands a better understanding of the neuropathophysiology of the disease, paving the way for better treatment efficacy. It has been speculated that a better understanding of critical clinical signatures that occur before the onset of symptoms and timely intervention with regard to these early signatures may reduce or prevent the onset of severe symptoms related to SZ [38] . However, significant progress toward these ends has not been reported. Maturation of the prefrontal cortex (PFC) via extensive synaptic pruning occurs during late adolescence and early adulthood, and thus it has been hypothesized that synaptic pruning that occurs in the PFC may play a critical role in the onset of SZ [39] . ECM molecules regulate processes occurring during late adolescence and early adulthood, including altered GABAergic function, synaptic pruning and plasticity, axonal guidance, neuronal differentiation, and neuronal migration [5] .
A number of immunohistochemical studies indicated patterns of ECM molecular expression associated with SZ [40] [41] [42] [43] [44] [45] (Table 2) . A marked decrease in the numbers of CSPG-labeled PNNs in the amygdala and entorhinal cortex of patients with SZ was reported [41, [73] [74] [75] [76] . The PNNs were detected with use of Wisteria floribunda agglutinin (WFA) lectin, which is believed to bind the GalNAc residue of CS in the PNNs [77] . Treatment with chondroitinase ABC, an enzyme known to degrade CS chains, abolished the WFA staining of PNNs, indicating the specificity of WFA for CSPGs [41] . Another study reported a decrease in the numbers of WFA-labeled PNNs in layers 3 and 5 of the PFC of patients with SZ compared with normal controls [42] . Intriguingly, an increase in the number of PNNs in the PFC during postnatal development through early adulthood has been reported [42] , suggesting a parallel relationship of PNN development with the onset of SZ symptoms and indicating the contribution of altered PNN expression to the onset of the disease. A similar decrease in the numbers of PNNs with use of antibodies against aggrecan, one of the main CSPGs in the amygdala, was observed for schizophrenic patients [44] . Another study quantified the densities and fluorescence intensities of parvalbumin neurons and PNNs labeled with WFA or immunoreactive against the major PNN protein, aggrecan, in schizophrenic patients and normal controls. They observed a decrease in the fluorescence intensities for both parvalbumin cells and PNNs labeled with WFA or immunoreactive against aggrecan. However, the densities of parvalbumin cells and PNNs were unchanged, suggesting that normal complements of parvalbumin neurons and PNNs are preserved in SZ but the levels of parvalbumin and PNN proteins and carbohydrate moieties on PGs that bind to WFA are dysregulated [46] . A significant reduction in the densities of cytoplasmic CSPG and olfactory receptor neurons in SZ has been reported, suggesting a reduction of CSPG expression in mature olfactory receptor neurons, which may contribute to the olfactory receptor neuron lineage dysregulation and olfactory identification abnormalities observed in SZ [42] .
Reelin, tenascin X, fibronectin, and integrins have been extensively investigated in SZ (Table 2) . Reelin is an extracellular glycoprotein that performs diverse roles in the developing and adult brain, including regulation of neuronal migration, synapse development, synaptic plasticity, and learning and memory. In patients with SZ, a reduced expression of both messenger RNA and protein levels of reelin was reported [48, 49] . Tenascin X is the largest member of the tenascin family of ECM glycoproteins. It is involved in behavioral functions, including anxiety, emotional learning, and memory [78] , and has been associated with SZ [79] [80] [81] . Fibronectin is a high molecular weight ECM glycoprotein that binds to integrin receptors and plays important roles in neurogenesis and synaptogenesis. Dysregulation of fibronectin may result in neurodevelopmental abnormalities related to the pathogenesis of SZ [52, 53] . In contrast, a study showed no significant association of fibronectin with SZ [82] . 
CSPG chondroitin sulfate proteoglycan, WFA Wisteria floribunda agglutinin, PFC prefrontal cortex, GlcNAcT N-acetylglucosamine transferase
Integrins assist in cell-cell and cell-ECM interactions and play a significant role in the maintenance and modulation of neuronal synaptic activity and development of the central nervous system, and have been associated with the pathophysiology of SZ. For example, altered expression of ITGA8 and ITGB3 has been observed in SZ [83, 84] . In addition, a flow cytometry study analyzed surface expression of several glycoproteins and found a significant increase in integrin α 2b β 3a expression in first-episode SZ patients compared with healthy controls [54] .
Levels of proteolytic enzymes, including matrix metalloproteases (MMPs), members of the a disintegrin and metalloprotease (ADAM) family, and members of the ADAM with thrombospondin motifs (ADAMTS) family, have been associated with SZ (Table 2 ) [85] [86] [87] [88] [89] . These enzymes mediate proteolytic ECM remodeling by interaction with cell adhesion molecules, ECM receptors, and CSPGs, and thus play important roles in synaptic plasticity [24] . Elevated levels of MMP-9 have been reported in previous SZ studies, including those of treatment-resistant schizophrenic patients [55, 56] . Additionally, altered messenger RNA expression of MMPs (MMP-16, MMP-24, MMP-25) and ADAMTS-1 and ADAMTS-6 has also been reported in SZ [47] . In contrast, a recent study showed no difference in the levels of MMP-9 in schizophrenic patients compared with healthy controls. However, this expression level was demonstrated to be sensitive to electroconvulsive therapy, where MMP-9 levels were significantly decreased in schizophrenic patients compared with healthy controls [57] .
Several genetic studies indicate abnormal CSPG expression in SZ (Table 2 ). For example, increased expression of receptor phosphotyrosine phosphatase beta/zeta (RPTPβ), a transmembrane CSPG involved in critical processes such as synaptic plasticity and learning, was observed in patients with SZ. The signaling of neuregulin 1, a multifunctional protein that performs an important role in the development of the central nervous system, was reduced in mice overexpressing RPTPβ [40] . Further, increased expression of PTPRZ1, the gene encoding RPTPβ, has been reported in the amygdala and PFC of schizophrenic patients [40, 58] . Altered expression of NCAN, a gene encoding the CSPG neurocan, has also been reported in SZ [90, 91] . CSPG5 has been indicated as the potential susceptibility gene for SZ, along with other integrating partners, including NRG1, ERRB4, and ERBB3 [92] . A recent study combining laser capture microdissection with gene expression profiling extracted RNA from lasercaptured pyramidal neurons from postmortem brains of schizophrenic patients and normal controls. A number of genes encoding CSPGs and associated with ECM, including ACAN, VCAN, LUM, and HAPLN1, were downregulated in SZ. In addition, altered expression of genes belonging to ECM-related pathways, including transforming growth factor β signaling, focal adhesion, and ECM-receptor interaction pathways, was observed [47] . These data strongly suggest a decrease in the levels of ECM structural components and enzymes that regulate ECM-related molecules and pathways in SZ.
Proteomics studies of schizophrenia
Proteomics studies using different methods, including labelfree liquid chromatography (LC)-tandem mass spectrometry (MS/MS), two-dimensional gel electrophoresis-mass spectrometry (2DE-MS), and two-dimensional difference in-gel electrophoresis-mass spectrometry (2D-DIGE-MS), have revealed several common altered proteins and pathways in SZ compared with normal control samples [93] (Table 2) . Altered proteins and pathways included enolase proteins (enolase 1, enolase 2), heat shock proteins (heat shock protein 60, heat shock protein family A member 8, heat shock protein family A member 5), vimentin, tubulin beta chain, 14-3-3 protein zeta/delta, 14-3-3 protein epsilon, septin 11, annexins A5 and A6, protein-L-isoaspartate (D-aspartate) O-methyltransferase, galectin 1, superoxide dismutase 1, glyceraldehyde 3-phosphate dehydrogenase, peroxiredoxins 1 and 5, and protein S100B, and pathways such as energy metabolism, oxidative stress response, cell growth and maintenance, cell signaling and interaction, cellular assembly and organization, oligodendrocyte dysfunction, and cytoskeleton structure assembly [51, [62] [63] [64] [65] [66] [67] [68] [69] . Some serum and blood-based biomarker studies have indicated sets of proteins that correlate with SZ. Examples of these are the growth factors vascular endothelial growth factor, EGF, and fibroblast growth factors, and intercellular adhesion molecule 1 [94] [95] [96] .
With respect to ECM, a recent study of the cytoplasmic proteome of a corpus callosum portion of the human brain from schizophrenic patients and normal controls illustrated 65 differentially expressed proteins, including the ECMrelated proteins versican and hyaluronan and PG link protein 2 which were observed to be downregulated in schizophrenic patients compared with normal controls [62] . Additionally, an extensive multiomics (genomics, proteomics, metabolomics) study indicated significant upregulation of ECM-related tenascin XB, but only at the gene level [51] .
Glycomics studies of schizophrenia
Given the inherent complexity of the human brain, studying only genetic or proteomic variation may not provide a complete picture of the pathophysiology of SZ and other neurodegenerative disorders. Since most of the ECM molecules are either PGs containing GAG side chains or glycoproteins containing N-linked and/or O-linked glycans, understanding glycosylation changes in SZ (and other disorders) is essential ( Table 2 ). Previous reports have suggested aberrant expression of genes (UGT8, SGPP1, GALC, B4GALT6, SPTLC2, ASAH1) particularly related to glycosphingolipid metabolism and Nlinked and O-linked glycan biosynthesis in patients with SZ compared with controls [72] . Moreover, a study on blood and cerebrospinal fluid (CSF) from schizophrenic patients and controls identified decreases in bisecting and sialylated N-glycosylation in schizophrenic patients. In addition, sex-based variations of N-glycans, including triantennary trisialylated glycan and tetraantennary tetrasialylated glycan with a polylactosamine extension, were observed between male and female schizophrenic patients [70] .
Alzheimer's disease
Alzheimer's disease (AD) is the leading cause of dementia and cognitive decline in aged populations. Amyloid beta (Aβ) A4 precursor protein (APP) is associated with the formation of amyloid plaques. Tau protein is involved in the formation of neurofibrillary tangles [97] . Studies have indicated roles of HSPGs and CSPGs in AD [98] [99] [100] [101] . HS has been shown to bind to and affect aggregation, intracellular internalization, and clearance of tau and APP [102] . It also regulates APP processing by β-site APP-cleaving enzyme 1 (BACE1), which cleaves β site of the amyloid protein [103] . In addition, HS enhances and stabilizes Aβ fibril formation [104] , dependent on the degree of sulfation of the HS [105, 106] . Several HSPGs, including perlecan, glypican, syndecan, and agrin, are associated with amyloid plaques in AD [104, [107] [108] [109] [110] [111] . Moreover, several reports have shown perlecan in senile plaques, neurofibrillary tangles, and amyloid-laden vessels [112] [113] [114] .
Among CSPGs, CS-A, CS-C, and unsulfated chondroitin are associated with lesions in AD [100] , and the DSPG decorin has been associated with amyloid plaques and neurofibrillary tangles in AD [115] . Intriguingly, appican, a CSPG modified alternatively spliced isoform of APP, has been observed to be expressed in astrocytes, but not neurons, in AD. Appican-enriched ECM serves as a better substrate for attachment of N2a neuroblastomas, pheochromocytoma PC12 cells, and primary astrocytes than APP-enriched ECM [101, 116] .
With respect to ECM, the distribution patterns of CSPGs in cortical areas of AD and normal human brains suggest that cortical neurons associated with PNNs and large proportions of hyalectan CSPGs were largely absent from neurofibrillary changes associated with AD [117] . Another study indicated decreases in the densities of WFA-labeled PNNs in AD compared with normal brain samples [118] . Contrastingly, aggrecan-based PNNs were shown to be unaffected in a transgenic (Tg2576) mouse model of AD [119] . Loss of CSPGs was reported in cells stained with Vicia villosa lectin, which binds to terminal GalNAc residues present in CSPGs and/or glycoproteins, in AD brains compared with normal brains [120] . Taken together, the findings suggest that ECM components, including CSPGs, and PNNs decrease in density in AD, and appear to play a neuroprotective role against tau lesions [121, 122] . Among other ECM components, hyaluronanpositive neurons were observed to remain unchanged in AD brains, suggesting resistance of such neurons to neuropathological processes related to AD [123] .
Because plaque formation characterizes AD, expression of Aβ-degrading enzymes or proteases that degrade Aβ peptides is an attractive therapeutic option. Examples of such enzymes include MMP-2, MMP-3, MMP-9, plasmin, neprilysin, and ADAM-10. ADAMs are increasingly recognized as targets for AD therapy [124] . Because ADAM-10 is an α-secretase involved in nonamyloidogenic cleavage of APP, upregulation of ADAM-10-mediated proteolysis could be a promising strategy to treat a neurodegenerative disorder such as AD [124] . In addition, upregulation of ADAM-10 messenger RNA expression in severe AD cases has been reported [125] , and mutations in ADAM10 have been associated with a reduction of α-secretase in familial late-onset AD [126] .
Among ECM glycoproteins, altered expression of reelin and its glycosylation patterns have been reported in CSF from AD patients [127] . A recent study showed perturbed expression of reelin and the downstream signaling members of the reelin pathway apolipoprotein E receptor 2, very low density lipoprotein receptor, and disabled 1 in AD. In addition, it was demonstrated that depletion of reelin is an early event of AD, occurring long before the onset of Aβ plaques, suggesting a possible role of decreased reelin expression in precipitation of AD and supporting it as a potential preclinical marker of AD [128] . Congruently, reduced expression of reelin in the entorhinal cortex of transgenic mice and humans with AD has been reported [129] . Additionally, reelin and the signaling members of the reelin pathway have been shown to inhibit Aβ generation, promote Aβ clearance, or prevent tau hyperphosphorylation in AD [130] [131] [132] .
The α V integrin plays an important role in mediating synaptic dysfunction before neurodegeneration in AD [133] . Also, the α 2 β 1 and α V β 1 integrin signaling pathways mediate Aβ-induced neurotoxicity in AD and may be a critical component of neurodegeneration [134] . The integrin lymphocytefunction-associated antigen 1 mediates infiltration of neutrophils to amyloid deposits in the brain. Inhibition of neutrophils or blockage of lymphocyte-function-associated antigen 1 mediated neutrophil trafficking in a transgenic AD mouse model was shown to reduce AD and improve memory in mice, suggesting a direct contribution of integrin-mediated neutrophil trafficking in AD pathogenesis and cognitive impairment [135] . APP regulates the activity of integrin β 1 by binding to it. On the shedding of APP by treatment with α-secretase, the inhibitory activity of APP is removed and neurite outgrowth is triggered via integrins [136] .
Proteomics studies of AD
In contrast to immunohistochemical studies that showed a reduction of the levels of ECM components and PNNs in AD, a recent proteomics study on a mouse model of AD demonstrated significant increases in the levels of several protein components of the ECM, including hyaluronan and PG link protein 1, neurocan, brevican, and tenascin R, with increases in Aβ levels in the hippocampus. These increases in expression occurred with impairment of long-term potentiation and contextual memory, before the onset of plaque formation. Injection of chondroitinase ABC into the hippocampus restored both long-term potentiation and contextual memory performance [137] . Another recent study used laser capture microdissection to excise hippocampal subareas CA1 and subiculum of 40 AD brains with subsequent LC-MS/MSbased proteomics. Among 372 altered proteins, the levels of several ECM components were increased in AD, including tenascin, versican, laminin subunit β 2 , and galectin 1. In addition, increases in the levels of adhesion molecules that interact with ECM, including CD44, integrin β 1 , and integrin α V , were observed in AD [138] . In contrast, the levels of versican and tenascin R were significantly decreased in frontal cortex AD brain tissue [139] . Table 3 summarizes the changes in ECM and related components in AD.
Other LC-MS/MS-based proteomics studies on AD brain have identified several proteins, including microtubuleassociated protein tau, APP, apolipoprotein E, ubiquitin carboxy-terminal hydrolase 1, syntaxin-binding protein 1, mitochondrial malate dehydrogenase, piccolo, transformation/transcription-domain-associated protein, 14-3-3 protein zeta/delta, and mucin 19, and pathways, including signal transduction, immune response, cytoskeleton organization, lipid metabolism, energy metabolism, glycolysis, apoptosis, oxidative stress, oxidative phosphorylation and synaptic functioning, that are significantly altered in AD [139] [140] [141] [142] [143] [144] [145] . Further, blood plasma and serum proteomics studies from AD and control samples have identified AD diagnostic biomarker candidates [146, 147] . For details on neuroproteomics in AD, see a recent review [148] .
Glycomics studies of AD
Both tau and APP carry N-and O-glycosylation. Further, tau protein N-glycosylation occurs only in individuals with AD and not in controls [149] . A recent study indicated glycosyltransferase III, an enzyme responsible for the formation of bisectingGlcNAc type N-glycans, is a promising target for AD therapeutics. It was also shown that BACE1, an enzyme required to cleave Aβ and generate Aβ plaques in AD, is posttranslationally modified with bisecting-GlcNAc type N-glycans in AD patients. With use of knockout mouse mutants lacking glycosyltransferase III, decreased cleavage of APP by BACE1 was observed, resulting in reduced densities of amyloid plaques and improved cognitive functions. It was suggested that because of lack of this sugar modification, BACE1 is directed toward late lysosomes, subjected to lysosomal degradation, and thus less colocalized with APP [150] . Consistent with this observation, an N-glycome profiling study indicated an increase in the levels of bisecting-GlcNAc type N-glycans and a decrease in overall sialylation in CSF from AD patients compared with normal controls [151] . The decrease in the levels of sialylated N-glycans in AD could be attributed to decreased sialyltransferase activity, which has been reported in serum as well as membrane and soluble fractions from postmortem brain of AD patients [152, 153] . In addition, lectin studies have shown decreased binding of wheat germ agglutinin, a lectin that binds to sialic acid residues, in CSF of AD patients [154, 155] . Other than sialylated and bisecting N-glycans, reduction of the level of NA2F, a corefucosylated biantennary terminal galactose N-glycan structure, has been reported in AD patients compared with healthy controls, and it has been suggested to serve as suitable serum N-glycan marker for AD [156] .
Current state of proteomics in studies of neurodegenerative disorders
Genomics and immunohistochemical analysis are widely used to study neurodegenerative disorders [41, 42, 47, 55, 117, 118, 122] . They have provided a base of information for N-Acetylgalactosamine residues stained by Vicia villosa lectin
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ADAM a disintegrin and metalloproteinase understanding the molecular deregulation associated with neurodegenerative disorders; however, genomics analysis does not sufficiently define the alterations at the protein level and associated biological functions. Expression and function of proteins can be modulated during transcription and translation and subsequently by post-translational modifications (PTMs), including phosphorylation, glycosylation, and acetylation. Proteomics analysis allows the identification and quantification of thousands of proteins from complex mixtures, together with the acquisition of PTM and protein-protein interaction information, which are important to understand the complete neuropathophysiology of these disorders. In recent years, significant advances have been made in neuroproteomics, with a large number of well-executed proteomics studies providing some common altered proteins and pathways. However, the lack of consistent results and followup studies remains a limiting factor. For example, a recent SZ proteomics study [62] compared its findings with those of previous studies [51, [63] [64] [65] [66] [67] [68] and found consistent alteration of only 30 proteins, including 14-3-3 protein zeta/delta, 14-3-3 protein epsilon, enolase 1, enolase 2, superoxide dismutase 1, glyceraldehyde 3-phosphate dehydrogenase, peroxiredoxin 1, and vimentin, and pathways, including energy and metabolism, cytoskeletal structure and function oxidative stress response, and oligodendrocyte dysfunction; however, the expression patterns of some of the proteins were observed to be in the opposite direction.
Similarly, for AD, a review [157] compared 43 twodimensional proteomics studies published between 1999 and 2010. A total of 93 proteins were differentially expressed in 13 different brain regions. Among these, only 42 altered proteins were found in more than one study, regardless of the brain region, and only 11 proteins (apolipoprotein A-I, apolipoprotein E, prostaglandin-H2 D-isomerase, transthyretin, aldolase A, fatty acid binding protein 3, glyceraldehyde 3-phosphate dehydrogenase, enolase 1, glial fibrillary acidic protein, peptidyl prolyl cistrans isomerase, ubiquitin carboxy-terminal hydrolase 1) were found to change in a similar direction in more than one study within the same brain region. For LC-MS/MS proteomics, a study [140] compared its 197 differentially expressed proteins with the findings of previous work [144, 145, [157] [158] [159] [160] and found only 19 common proteins, including APP, 14-3-3 protein zeta/delta, peroxiredoxin 1, annexin A1, and heat shock protein family A member 12A, changed in the same direction.
Low concordance was observed for differential proteins, whereas high concordance was observed for nondifferential proteins. The low concordance rate of the altered proteome among different studies leads to inconsistent conclusions regarding pathological patterns related to these disorders. It is difficult to compare proteomics studies because several points of variation can emerge depending on the type of sample used, the sample handling techniques, and the mass spectrometry methods. As shown in Table 4 , several recent proteomics studies for SZ and AD used different brain regions and a wide range of sample handling techniques and mass spectrometry instrumentation, leading to variable data, and only a few similarities in the findings, as indicated above. Increased use of standardized methods will improve the ability to compare protein expression in brain proteomics.
The human brain is a complex structure, with cellular and ECM heterogeneity based on the brain region. Thus, studies covering different brain regions make proteomics analysis much more challenging. In addition, studies on the human brain may have been affected by the postmortem interval and differences in tissue processing procedures [164] . Nevertheless, there remains an overwhelming need to characterize protein expression in both postmortem brains and animal models [165] . A recent study indicated a significant variability in quantitative LC-mass spectrometry proteomics of human brain tissue samples arising from the extraction methods (72 %) and other variables, including instrumental variance (16 %), instrumental stability (8.4 %), and proteolytic digestion (3.1 %) [166] . Because of this variability, it is necessary to analyze a large cohort of biological samples to validate the findings with enough statistical significance. In addition, differences in results could also be attributed to the method of separation and fractionation. Two-dimensional gel electrophoresis, later modified to two-dimensional difference in-gel electrophoresis, were two methods of choice in the past two decades. However, these gel-based techniques involve certain limitations, including low sensitivity and underrepresentation of some low-abundance and low-solubility membrane proteins [167] [168] [169] . Gel-free approaches using LC directly coupled with mass spectrometry have been used for label-free or label-based quantitative proteomics to overcome such limitations. Although label-based quantitative proteomics allows accurate protein profiling, the limitations of such approaches include additional time-consuming sample preparation, the requirement of larger sample amounts, the risk of incomplete labeling, and the cost of the (commercial) reagents. Label-free quantitative proteomics is, therefore, an attractive alternative since it uses a robust, reasonably accurate, straightforward, and time-effective experimental workflow.
For neuroproteomics, most studies have taken a discovery approach, and not all have performed orthogonal validation of the findings (Table 4) . Minimal attention has been paid to ECM-related proteins and PTMs, with very few studies indicating modifications of the proteins and ECM proteins among differentially expressed proteins. Importantly, many of these proteomics studies lacked relevant information, including complete proteome lists, peptide lists, sequence coverage, and modifications. Such information is of high relevance to the neuroproteomics community for cross-validation and comparison of the data to understand the neuropathophysiology.
ECM-related proteins were observed to be differentially expressed in only six studies (Table 4) . Versican, one of the AMT accurate mass and time, 2D-DIGE two-dimensional difference in-gel electrophoresis, 1DE one-dimensional gel electrophoresis, 2DE two-dimensional gel electrophoresis, IHC immunohistochemistry, MALDI matrix-assisted laser desorption/ionization, TOF time of flight, QTOF quadrupole time of flight, iTRAQ-IEF isobaric tags for relative and absolute quantitation-isoelectric focusing a Percent not included, peptide sequence information provided hyalectans, was differentially expressed in three of those six studies [62, 138, 139] . Notably, all three studies were performed as shotgun proteomics experiments, with label-free LC-MS/MS analysis, using an LTQ Orbitrap instrument. The peptide sequence coverage for versican identified by two of the three studies (one study did not provide sequence coverage information) is shown in Fig. 2 . One study [139] identified 8 % sequence coverage (yellow in Fig. 2 ), whereas another study [138] identified 17 % sequence coverage (red in Fig. 2 ). Major domains covered by these studies were immunoglobulin-like V-type (21-146), link 1 (150-245), link 2 (251-347), EGF-like 2, calcium binding (3176-3290), and C-type lectin (3294-3354) domains. Some peptides from GAG regions (GAG-α, 348-1335; GAG-β, 1336-3089) were also covered (Fig. 2 ).
Future directions
Previous proteomics studies of neurodegenerative disorders, including SZ and AD, show a lack of concordance with respect to differentially expressed proteins and associated pathways, which could be due to technical variability among different studies, including difference in samples (number of samples, different brain regions), sample handling (two-dimensional gel electrophoresis, two-dimensional difference in-gel electrophoresis, LC-MS/MS), and mass spectrometers (Orbitrap, quadrupole time of flight, tandem time of flight) ( Table 4) . Several steps can be taken to rule out such technical limitations and to obtain reliable and confident proteome profiles, such as use of a larger cohort of samples, robust and appropriate biological models with the correct controls, validation of protein expression levels by use of a sufficient number of biological and technical replicate experiments, stringent data analysis, cross-validation of regulated proteins using orthogonal molecular techniques (e.g., Western blotting, multiple reaction monitoring, and ELISA), and use of ultraperformance high-end mass spectrometers. Furthermore, although PTMs play important roles in regulating protein expression and related biological pathways [170] , they have received very little attention in neuroproteomics. There is a need to perform in-depth analysis of global proteome data, since proteomics experiments deliver thousands of peptide fragments, and thus there are substantial chances of finding modified peptides. Since modified peptides are present in low abundances compared with non-modified peptides, the use of enrichment methods will likely increase the relative abundances of post-translationally modified peptides in the protein mixtures. Some examples of enrichment techniques include immunoprecipitation, affinity chromatography, and chemical derivatization.
A plethora of altered proteins and biological pathways have been identified in neuroproteomics, but, disappointingly, only a handful of proteomics studies have identified altered ECM components. Nonetheless, some immunohistochemical and genomics studies have indicated changes in neural ECM associated with neurodegenerative conditions. Thus, given the importance of ECM components in neurodegenerative disorders, future neuroproteomics studies should target such ECM proteins for a better understanding of the neuropathophysiology. At present, despite low concordance and the lack of additional information, studies have provided a large amount of information and a large number of datasets contributing to the knowledge base for understanding the complex neuropathophysiology of neurodegenerative disorders.
